Revance Therapeutics (STU:RTI) Buyback Yield % : -25.62 (As of Mar. 04, 2025)

View and export this data going back to 2015. Start your Free Trial

What is Revance Therapeutics Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Revance Therapeutics's current buyback yield was -25.62%.

Revance Therapeutics Buyback Yield % Historical Data

The historical data trend for Revance Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revance Therapeutics Buyback Yield % Chart

Revance Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Buyback Yield %

Get a 7-Day Free Trial

-26.78

-4.53

-1.86

-16.62

-13.22

Revance Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Buyback Yield %	Get a 7-Day Free Trial															-9.95	-12.96	-38.51	-36.24	-17.93

Competitive Comparison of Revance Therapeutics's Buyback Yield %

For the Biotechnology subindustry, Revance Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revance Therapeutics's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revance Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Revance Therapeutics's Buyback Yield % falls into.

Revance Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Revance Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	91.868)	/	694.9077
	=	-13.22%

Revance Therapeutics's annualized Buyback Yield for the quarter that ended in Sep. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(TTM)		/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	(TTM)^**	/	Market Cap
	=	- (0	+	89.816)		/	486.71744
	=	-18.45%

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Revance Therapeutics Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Revance Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (STU:RTI) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

RVNC:USA

Address

1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203

Website

https://www.revance.com

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Revance Therapeutics Headlines

No Headlines